Evaluation of capture and amplicon-based targeted sequencing methods on formalin-fixed tumours

ABSTRACT: Evaluated performance of three capture (Agilent’s SureSelectXT HS, Illumina’s Nextera Rapid Capture Custom, and New England Biolabs’ Next Direct Custom) and one amplicon-based (Qiagen’s Human Breast Cancer Panel) targeted sequencing methods on paired blood and FFPE, using whole exome sequencing data from matched fresh-frozen tissue as a comparison.

PROVIDER: EGAS00001004965 | EGA |

REPOSITORIES: EGA